Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa fda approval date

besponsa fda approval date

Перейти к контенту

Главное меню:

Разное
besponsa fda approval date
Besponsa (inotuzumab ozogamicin) FDA Approval History , BESPONSA (inotuzumab ozogamicin) Lyophilized Powder, FDA approves new treatment for adults with relapsed or , Besponsa New FDA Drug Approval | CenterWatch, FDA approvals due for Maviret and Besponsa - evaluate.com, FDA Approvals Due For Maviret And Besponsa | Seeking Alpha, , , .
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 May 2019), Cerner Multum™ (updated 2 May 2019), Wolters Kluwer™ (updated 1 May 2019) and others.. Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Development History and FDA Approval Process for Besponsa. Company: Wyeth Pharmaceuticals, Inc. Application No.: 761040 Approval Date: 08/17/2017. Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance..
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. Besponsa (inotuzumab ozogamicin): For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. New approved drug details including side effects, uses and general information.. CD22 target. Last month Pfizer’s inotuzumab ozogamicin, trademarked Besponsa, gained European approval as a monotherapy for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).. Besponsa's approval should be of interest to followers of CAR-T therapies, some of which target the same CD22 antigen. Although an antibody-drug conjugate is unlikely to elicit the same efficacy . . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню